Research on chemotherapy and its side effects. Covers nerve-injury prevention, gold-nanorod therapy, less-intensive regimens, and combination treatments.
Researchers at Children's Hospital Los Angeles found that targeting survivin enhances chemotherapy effectiveness in retinoblastoma cells and mouse models. The combination of a survivin inhibitor with chemotherapy agents increased Rb cell death, demonstrating a therapeutic advantage.
A new hybrid drug combines parts of chloroquine and a chemoreversal agent to counteract malaria resistance. The dual-acting mechanism kills the parasite by concentrating the drug in its stomach.
Researchers at CNIO have identified a protein, CDC25A, as a determinant of chemotherapy resistance in cancer cells. They used CRISPR genome editing technology to test various mutations and found that cells with this mutation were resistant to treatment.
Patients with grade 2 glioma who received radiation therapy plus PCV chemotherapy experienced longer progression-free and overall survival times compared to those who received radiation therapy alone. The treatment combination improved survival rates by up to 10 years.
A phase 1b clinical trial shows that an experimental therapy can control pancreatic cancer tumors well enough to make patients eligible for surgery. The treatment, PF-04136309, was found to be safe and effective when combined with chemotherapy.
Researchers have discovered that high doses of cyclophosphamide can selectively kill reactive immune cells, reducing the severity of graft-versus-host disease (GVHD) in patients. This breakthrough has paved the way for the use of mismatched donors in stem cell transplantation, improving access to treatment for many patients.
A new study reveals that despite the availability of lung cancer tests and treatment to 70% of the world's population, large discrepancies exist in patient access. The study found that many poorer countries lack access to essential tests and treatments due to high costs and low HDI scores.
Scientists developed triple-stage nanoparticles that improve tumor penetration and release cisplatin in acidic conditions, enhancing its efficacy while reducing toxic side effects. The delivery system demonstrated significant improvements in anti-tumor activity against various cancer models.
A study published in Antimicrobial Agents and Chemotherapy found that patients with S. aureus skin and soft tissue infections took only 57% of their prescribed antibiotic doses after leaving the hospital. This led to nearly half of them getting a new infection or requiring additional treatment.
Researchers developed a new technique using nanoparticles that deliver therapeutic payloads and glow green when cancer cells begin dying. This allows for early detection of treatment effectiveness, potentially improving patient outcomes and quality of life.
A study published in The Lancet Oncology found that most female childhood cancer survivors can conceive, but male survivors are less likely to father a child due to chemotherapy exposure. Female survivors treated with certain drugs like ifosfamide and cisplatin may face challenges conceiving, particularly after age 30.
African American patients are less likely to receive a common genomic test that predicts the seriousness of early-stage breast cancer. The study found higher scores among African Americans, indicating an increased likelihood of aggressive tumor biology benefiting from chemotherapy.
Researchers at Queensland University of Technology have developed a new 3D printable material that mimics human tissue, allowing for the creation of tumor microenvironments to test anti-cancer drugs. This breakthrough enables rapid, personalized cancer treatment targeting tumors, not entire bodies.
Researchers have synthesized novel selenohydantoins with promising anticancer and antioxidant activity, leveraging the potential of selenium to slow down oxidation processes. The study's findings highlight the importance of structural modification in influencing biological activity.
A new study from the University of Texas M. D. Anderson Cancer Center found that neurofeedback significantly reduces chronic pain and improves quality of life in cancer patients with chemotherapy-induced neuropathy. The treatment, which uses electroencephalogram biofeedback to modify brain activity, showed a 73% improvement rate in pai...
A new study found that a 21-gene test can identify patients with early breast cancer who can be spared chemotherapy and still survive five years after diagnosis. The trial showed a 94% disease-free survival rate among low-risk patients treated with hormone therapy alone.
A clinical trial found that approximately a quarter of women with HER2 positive breast cancer who received combination treatment experienced significant tumor shrinkage or disappearance within 11 days. This discovery offers the possibility of tailoring treatment for each woman, potentially reducing the need for chemotherapy.
A new study found that low expression of SMARCA4/BRG1 gene in lung tumors may indicate patients who will benefit from certain chemotherapy regimens. The findings suggest an alternative therapy for these patients to spare them from cisplatin's side effects and allow them to try a different treatment sooner.
Researchers at Rice University have developed a new method for synthesizing the potent anti-cancer agent trioxacarcin, which damages DNA and disrupts cancer cell replication. This breakthrough allows for more efficient production of these valuable molecules, enabling their study as potential new medications.
Researchers found that dose-dense adjuvant chemotherapy significantly improved overall survival after ten years by nearly a third compared to standard interval regimens. Dose-dense chemotherapy was not associated with an increased risk of treatment-induced amenorrhea, and it seemed effective irrespective of hormone receptor status.
Nanoparticulate drug carriers show promise in targeted cancer therapy, increasing therapeutic concentrations at tumor sites while minimizing harm to healthy tissues. This approach has the potential to improve treatment efficacy and reduce systemic toxicity.
Researchers identified 12 classes of drugs and 4 main mechanisms that can cause small arteries to constrict in response to cold, limiting blood supply. A recent study published in British Journal of Clinical Pharmacology highlights the need for further investigation into this condition.
Researchers at St. Joseph's Hospital and Medical Center found that a standard front-line treatment for advanced ovarian cancer should involve every three week chemotherapy with carboplatin, paclitaxel plus bevacizumab, or weekly dose intense paclitaxel without bevacizumab
Using laser probe, neurosurgeons deliver chemotherapy drugs to patients with glioblastoma after opening the blood-brain barrier. The technology allows for longer treatment windows and potentially limits harmful effects of chemotherapy.
Researchers develop adaptive therapy that adjusts drug dose based on tumor response, controlling growth and allowing 60-80% of mice to be weaned off the drug. The treatment approach stabilizes tumors by maintaining a small population of drug-sensitive cells to suppress resistant cell growth.
Researchers have found that laser ablation creates a temporary opening in the blood-brain barrier, allowing chemotherapy drugs to pass into the brain. This breakthrough raises hopes for longer treatment options and improved patient outcomes.
Researchers at MDI Biological Laboratory have discovered two drugs that could reverse peripheral nerve damage caused by chemotherapy, with applications also for diabetes and traumatic injuries. The drugs reduce MMP-13 activity, preventing degeneration of axons and restoring touch response in zebrafish.
A large-scale analysis of patient records found that chemotherapy before radiation therapy did not improve overall survival rates for head and neck cancer patients. Patients who received concurrent chemotherapy and radiation had slightly longer median overall survival times compared to those receiving chemotherapy alone.
Researchers from Case Western Reserve University have developed a new image analytics test that can reliably distinguish between patients who need only hormonal treatment and those who also need chemotherapy. The test uses MRI data to identify molecular changes in tissues, which can be analyzed quickly and cost-effectively.
A new study suggests that patients with resectable pancreatic cancer should receive at least 6 months of adjuvant chemotherapy to reduce distant disease recurrences and improve overall survival. Chemotherapy, but not chemoradiotherapy, significantly reduces the incidence of distant recurrence.
A recent clinical study found that ONC201 caused cell death in various tumor types, even when the p53 protein was mutated or deleted. The drug has shown promise in treating hematological malignancies, including leukemia and lymphoma patients, with clinical trials recently initiated.
Researchers from Massachusetts General Hospital report that inducing cytotoxic T cell infiltration into lung tumors can make them sensitive to checkpoint blockade. Combining chemotherapy with immune checkpoint therapies achieves long-lasting control of tumor growth in animal models, expanding the potential for effective treatment.
Researchers found that pediatric ALL patients treated with chemotherapy alone remain at risk for attention and learning problems, even after treatment ends. The study, published in the Journal of Clinical Oncology, suggests that early intervention is crucial to prevent academic difficulties.
A new study from Children's Hospital Los Angeles found that leukemia therapy leads to a significant drop in bone mineral density during the first month of treatment, affecting the lower spine and legs. This earlier onset than previously thought highlights the need for new approaches to mitigate bone toxicity in cancer patients.
Researchers at Rockefeller University have captured atomic images of the herpes simplex 1 virus revealing how it inserts itself into another protein to evade detection by immune cells. The study provides a mechanistic explanation for the virus's ability to escape immune system recognition.
A study by University of Minnesota researchers identified the mechanism of 5-azacytidine, a DNA-based drug that blocks HIV's ability to spread. The drug converts to a DNA form and infiltrates HIV when it turns RNA into DNA, stopping replication.
A portable method to detect tainted medicines and supplements has been developed by a CWRU researcher, potentially improving public health globally. The device uses Nuclear Quadrupole Resonance spectroscopy to authenticate good medicines and supplements, while also addressing the issue of counterfeit products.
Experts have issued a framework to guide difficult prioritization decisions among children in need of scarce life-saving chemotherapy treatment. The modified utilitarian model maximizes total benefit from available supply, considering factors like curability, prognosis, and drug importance.
Microtubules can spontaneously form large networks through the interaction of motor proteins. This self-organization is crucial for cell division and may inspire new materials and drug designs. Researchers developed a model describing this behavior, which could lead to breakthroughs in biology and material science.
A three-year study funded by PCORI investigates the safety and patient preferences of discharge strategies after chemotherapy for children with acute myeloid leukemia. The study aims to gather data on bloodstream infections and chemotherapy delays to inform better care for these vulnerable patients.
Chemotherapy can reduce the body's immune response, leaving breast cancer survivors vulnerable to illnesses. Researchers found that levels of lymphocytes and antibodies dropped significantly after chemotherapy, with only partial recovery in some cases.
A new biomarker, CDX2, has been identified that predicts which stage II colon cancer patients may benefit from chemotherapy. The study found that tumors lacking CDX2 expression were more likely to benefit from adjuvant chemotherapy than those with CDX2 expression.
Researchers have identified a biomarker, CDX2, that can predict which Stage II colon cancer patients are most likely to benefit from chemotherapy after surgery. The study found that patients without CDX2 had poorer outcomes, but those treated with chemotherapy had improved survival rates.
A new treatment model recommends aggressive surgery followed by targeted chemotherapy to achieve a 50% cure rate for women with advanced-stage ovarian cancer. This approach differs from current conventional treatments, which often result in a 20% survival rate.
Researchers have discovered a way to light up a common cancer drug, allowing them to see where the chemo goes and how long it takes to get there. This breakthrough could lead to more personalized medicine and better understanding of how cells interact with drugs.
Scientists have developed a new strategy for constructing highly specific synthetic pores using DNA, which can control the release of therapeutics. The pores are designed to act like doors, opening only when provided with the right key, allowing for precise targeting of drugs to specific tissues.
Researchers developed a device that produces tiny capsules with multiple inner ingredients, which can be triggered to mix and release toxic product only near the tumor site. The method has shown promise for increasing drug efficiency while reducing side effects in cancer treatment.
Researchers from the Repurposing Drugs in Oncology project have found that diclofenac, a common painkiller, has significant anti-cancer properties. The study suggests that existing non-cancer drugs may represent a valuable source of novel therapies for cancer treatment.
A new study reveals that docetaxel retains effectiveness in patients with castration-resistant metastatic prostate cancer (mCRPC) treated with abiraterone. Following abiraterone, 40% of patients experienced a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this drug sequencing.
A study by CNIC researchers has identified a new mechanism through which blood stem cells regulate their proliferation and microenvironment. The protein ESL-1 controls the production of TGF-, a cytokine with antiproliferative properties, and is essential for maintaining HSCs in diseases like anemia.
Researchers from Colorado State University have discovered that RNA plays a crucial role in DNA damage, leading to mutations and disease. The study sheds light on the mechanisms behind Aicardi-Goutieres syndrome and has implications for cancer research.
A study found that women with breast cancer who received chemotherapy and triptorelin had a higher long-term probability of ovarian function recovery without affecting pregnancy rates or disease-free survival. The treatment showed modest benefits regarding potential prevention of treatment-associated infertility.
Researchers have developed models to rationalize the action of chemotherapeutic molecules on body cells, enabling better understanding of how drugs interact with biological targets. The study aims to improve the design of new therapeutic molecules, resulting in more effective and side-effect-free drugs.
The LUX-Lung 7 trial shows afatinib significantly improved progression-free survival, time-to-treatment failure and objective response rate compared to gefitinib. Afatinib is considered the EGFR tyrosine kinase inhibitor of choice for first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer.
Researchers discovered that aggressive tumors hijack an export pathway in cells to lay the groundwork for cancer progression and resistance to chemotherapy. Blocking this pathway may help restore tumor vulnerability to chemotherapy.
Researchers found that combining TTFields with chemotherapy significantly improved progression-free and overall survival for patients with glioblastoma. The study, published in JAMA, suggests a potential new treatment approach for this devastating brain tumor.
A recent study published in Endocrinology Today holds promise for cancer patients undergoing chemotherapy to protect their fertility and defense systems. Researchers found that the potent humanin analogue (HNG) protected male germ cells and white blood cells, reducing infertility and infection susceptibility.
A new study from MD Anderson Cancer Center found that delaying chemotherapy after surgery increases the risk of death for breast cancer patients, particularly those with triple-negative breast cancer. Patients who start treatment within 90 days have a lower risk of death compared to those who delay it.
Studies found that patients with delayed breast cancer surgery and chemotherapy had poorer overall and disease-specific survival rates. A delay of up to 90 days in receiving chemotherapy was associated with no adverse outcomes, but prolonged delays led to increased risks of death from the disease.
Adding carboplatin to presurgery chemotherapy significantly improved disease-free survival rates for patients with triple-negative breast cancer (TNBC). The study found that patients with pathologic complete responses had the lowest risk of relapse, supporting the use of carboplatin as a standard part of neoadjuvant therapy regimens.